Show simple item record

dc.contributor.authorBilici, Ahmet
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:36:25Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:36:25Z
dc.date.issued2015en_US
dc.identifier.citationBilici, A. (2015). Advances in the management of unresectable or metastatic pancreatic neuroendocrine tumors: Chemotherapy, targeted therapy, hormonal treatment, and future directions. Asian Pacific Journal of Cancer Prevention, 16(6), 2151-2159. https://dx.doi.org/10.7314/APJCP.2015.16.6.2151en_US
dc.identifier.issn1513-7368
dc.identifier.urihttps://hdl.handle.net/20.500.12511/1155
dc.identifier.urihttps://dx.doi.org/10.7314/APJCP.2015.16.6.2151
dc.description.abstractPancreatic neuroendocrine tumors (pNETs) are rare and heterogenous tumors and surgery to remove the primary tumor is the mainstay of treatment for resectable disease. However, curative surgery is often not feasible, because half of patients with pNET have metastases at the time of diagnosis. Palliative dubulking surgery and liver-directed therapies are appropriate options for these patients. Streptozocin-based regimens are standard, although temozolamide-based treatments are rapidly gaining wide clinical application. Somatostatin analogs are mainly indicated in hormonally active tumors to ameliorate symptoms. In addition, anti-tumoral activity has been proven in well-differentiated NETs. Recently, there has been tremendous progress in the molecular biology of pNETs; thereby, the efficacy of sunitinib and everolimus in the treatment of patients with metastatic pNETs has been proven by large placebo-controlled phase III trials. Currently, there are no definitively proven predictive biomarkers to evaluate response to medical therapies in patients with pNET. Therefore, further studies are needed to individualize and optimize their management. This article reviews systemic chemotherapy, targeted therapies, and anti-secretory treatments for the management of patients with unresectable or metastatic pNETs, summarized in the light of recent advances.en_US
dc.language.isoengen_US
dc.publisherAsian Pacific Organization for Cancer Preventionen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChemotherapyen_US
dc.subjectNeuroendocrine Tumorsen_US
dc.subjectPancreaticen_US
dc.subjectSomatostatin Analoguesen_US
dc.subjectTargeted Therapyen_US
dc.titleAdvances in the management of unresectable or metastatic pancreatic neuroendocrine tumors: Chemotherapy, targeted therapy, hormonal treatment, and future directionsen_US
dc.typeotheren_US
dc.relation.ispartofAsian Pacific Journal of Cancer Preventionen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume16en_US
dc.identifier.issue6en_US
dc.identifier.startpage2151en_US
dc.identifier.endpage2159en_US
dc.relation.publicationcategoryDiğeren_US
dc.identifier.doi10.7314/APJCP.2015.16.6.2151en_US
dc.identifier.scopusqualityQ2en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record